United-Guardian, Inc. reported a decrease in total sales for the fiscal year ending December 31, 2025, with revenues falling approximately 13% to $10.5 million from $12.2 million in 2024. The decline was primarily attributed to a significant drop in sales of cosmetic ingredients, which decreased by 45% to $3 million, largely due to reduced demand from their largest distributor, Ashland Specialty Ingredients (ASI). In contrast, sales of pharmaceutical products increased by 15% to $6.2 million, driven by higher orders from major pharmaceutical wholesalers, while medical lubricants saw a modest increase of 4% to $2.1 million.
The company's financial performance reflects notable shifts compared to the previous fiscal period. The gross profit margin decreased to 49% from 53% in 2024, primarily due to the lower sales volume of higher-margin cosmetic ingredients. Operating expenses rose by 3% to $2.4 million, influenced by increased payroll and consulting fees related to their key pharmaceutical product, Renacidin. Research and development expenses also saw a slight increase, totaling $463,644, as the company continues to focus on innovation and product development.
Strategically, United-Guardian entered a new distribution agreement with Brenntag Specialties in January 2026, aimed at expanding the market for its Natrajel line of sexual wellness ingredients across North America and France. Although there were no sales from this product line in 2025, the company is poised to begin manufacturing and distribution in 2026. The company has also been actively working on enhancing its product portfolio to meet the growing demand for natural and sustainable ingredients, which is a priority for many of its customers.
Operationally, United-Guardian maintained a workforce of 25 employees, with a focus on research, quality control, and manufacturing. The company reported an increase in accounts receivable, reflecting higher sales in the fourth quarter of 2025, and a current ratio improvement from 6.6 to 1 in 2024 to 7.3 to 1 in 2025, indicating a stronger liquidity position. The company continues to face competitive pressures, particularly from lower-cost manufacturers in Asia and Europe, but remains committed to leveraging its innovation capabilities and high-quality product offerings to maintain market share.
Looking ahead, United-Guardian anticipates modest increases in operating expenses and research and development costs as it seeks to capitalize on emerging market opportunities and enhance its product offerings. The company is also navigating challenges related to global supply chain instability and changing trade policies, which could impact sales and operational costs. Despite these challenges, United-Guardian is focused on sustaining its growth trajectory through strategic partnerships and product innovation.
About UNITED GUARDIAN INC
United-Guardian, Inc. specializes in manufacturing and developing specialty cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness products. The company focuses on innovative, environmentally friendly formulations, serving global markets through distributor partnerships. Its core value lies in product innovation, quality, and reliability, with a business model centered on research, proprietary formulations, and strategic distribution to healthcare, personal care, and sexual wellness sectors.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.